Key result
Invasive coronary reactivity testing remains the gold standard for diagnosing coronary microvascular dysfunction in women, while non-invasive imaging like PET and CMR hold promise for future detection.
This review highlights the importance of diagnosing coronary microvascular dysfunction in women, emphasizing invasive coronary reactivity testing as the gold standard and noting the potential of non-invasive imaging.
Clinicians should continue relying on invasive reactivity testing for CMD diagnosis in women; leaves open prospective validation of PET and CMR.
Coronary microvascular dysfunction (CMD) also known as syndrome X, is characterized by typical anginal symptoms, evidence of myocardial ischemia on non-invasive testing and normal to minimal coronary disease on coronary angiography. It has a female preponderance and has been detected in up to 50% of women presenting with chest pain symptoms. Definitive diagnosis of CMD is critical as recent evidence suggests that women with this condition are at increased risk of cardiovascular events in the future. Invasive coronary reactivity testing on coronary angiography is considered to be the 'gold standard' for diagnosis of CMD. Non-invasive imaging techniques such as PET and cardiac magnetic resonance hold promise for detection of CMD in the future.
No takes yet. Share an insight, caveat, or question.
Kuruvilla et al. (2013) conducted a review in Coronary microvascular dysfunction (CMD). Diagnostic strategies (invasive coronary reactivity testing, PET, cardiac magnetic resonance) was evaluated. Invasive coronary reactivity testing remains the gold standard for diagnosing coronary microvascular dysfunction in women, while non-invasive imaging like PET and CMR hold promise for future detection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: